Información:
Error:
ID
12909
Descripción
Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result; ODM derived from: https://clinicaltrials.gov/show/NCT00146120
Link
https://clinicaltrials.gov/show/NCT00146120
Palabras clave
Versiones (1)
- 6/1/16 6/1/16 -
Titular de derechos de autor
CC BY-NC 3.0
Subido en
6 de enero de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Acute Myeloid Leukemia NCT00146120
Eligibility Acute Myeloid Leukemia NCT00146120
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT00146120
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
patients with aml, de novo or secondary after myelodysplasy, or with therapy-induced aml after healed primary malignom; or refractory anemia with excess of blasts in transformation (raeb-t); the diagnosis must be confirmed morphological, cytochemical and with immunological phenotyping
Item
patients with aml, de novo or secondary after myelodysplasy, or with therapy-induced aml after healed primary malignom; or refractory anemia with excess of blasts in transformation (raeb-t); the diagnosis must be confirmed morphological, cytochemical and with immunological phenotyping
boolean
C0023467 (UMLS CUI [1])
C0002893 (UMLS CUI [2])
C0002893 (UMLS CUI [2])
cytogenetical tests must be performed for each patient
Item
cytogenetical tests must be performed for each patient
boolean
C0010802 (UMLS CUI [1])
age: 16 - 60 years
Item
age: 16 - 60 years
boolean
C0001779 (UMLS CUI [1])
all patients have to be informed about the character of the study. written informed consent of each patient at study entry.
Item
all patients have to be informed about the character of the study. written informed consent of each patient at study entry.
boolean
C0021430 (UMLS CUI [1])
organic insufficiency: insufficiency of the kidneys (crea > 1.5 x upper normal serum level), or insufficiency of the liver (bilirubin, sgot or ap > 2 x upper normal serum level) uncaused by the aml; severe obstruction or restrictive ventilation disorder, heart failure with a ejection fraction < 0.5
Item
organic insufficiency: insufficiency of the kidneys (crea > 1.5 x upper normal serum level), or insufficiency of the liver (bilirubin, sgot or ap > 2 x upper normal serum level) uncaused by the aml; severe obstruction or restrictive ventilation disorder, heart failure with a ejection fraction < 0.5
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0035204 (UMLS CUI [3])
C0232174 (UMLS CUI [4])
C1278039 (UMLS CUI [2])
C0035204 (UMLS CUI [3])
C0232174 (UMLS CUI [4])
secondary malignom
Item
secondary malignom
boolean
C0006826 (UMLS CUI [1])
other severe diseases
Item
other severe diseases
boolean
C0009488 (UMLS CUI [1])
pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
participation in an concurrent clinical study
Item
participation in an concurrent clinical study
boolean
C2348568 (UMLS CUI [1])